Literature DB >> 1559127

Decreased inhibition by gravidin of arachidonate release from transformed compared to nontransformed cells.

T Wilson1, R K Ralph, R Ganendren.   

Abstract

1. Gravidin (a phospholipase A2 inhibitor) reduced the release of arachidonic acid from human lymphocytes by 51% at 10(-8) M. 2. Under normal culture conditions, nanomolar gravidin caused a significant reduction in the release of free arachidonic acid from human lymphocytes or nontransformed fibroblasts but in transformed cells, nanomolar gravidin was ineffective. 3. Inhibition of arachidonate release appeared to be related to rate of growth as inhibitory effects of gravidin on Jurkat cells and HL-29 cells could be observed if the cells were cultured under conditions where DNA synthesis was low. 4. The reported disparate effects of lipocortin on cell phospholipase A2 activity may be reconciled if DNA synthesis is investigated.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1559127      PMCID: PMC1908657          DOI: 10.1111/j.1476-5381.1992.tb14251.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  14 in total

1.  Gravidin, an endogenous inhibitor of phospholipase A2 activity, is a secretory component of IgA.

Authors:  T Wilson; D L Christie
Journal:  Biochem Biophys Res Commun       Date:  1991-04-15       Impact factor: 3.575

2.  Paradoxical stimulation of both lipocortin and prostaglandin production in human amnion cells by dexamethasone.

Authors:  M D Mitchell; F D Lytton; L Varticovski
Journal:  Biochem Biophys Res Commun       Date:  1988-02-29       Impact factor: 3.575

3.  Effects of glucocorticoids on prostaglandin formation by human amnion.

Authors:  W Gibb; J C Lavoie
Journal:  Can J Physiol Pharmacol       Date:  1990-06       Impact factor: 2.273

4.  Glucocorticoids induce the formation and release of anti-inflammatory and anti-phospholipase proteins into the peritoneal cavity of the rat.

Authors:  G J Blackwell; R Carnuccio; M Di Rosa; R J Flower; C S Langham; L Parente; P Persico; N C Russel-Smith; D Stone
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

5.  The effects of indomethacin and a beta-sympathomimetic agent on the fetal ductus arteriosus during treatment of premature labor: a randomized double-blind study.

Authors:  M Eronen; E Pesonen; T Kurki; O Ylikorkala; M Hallman
Journal:  Am J Obstet Gynecol       Date:  1991-01       Impact factor: 8.661

6.  Partial purification and characterisation of two compounds from amniotic fluid which inhibit phospholipase activity in human endometrial cells.

Authors:  T Wilson; G C Liggins; G P Aimer; S J Skinner
Journal:  Biochem Biophys Res Commun       Date:  1985-08-30       Impact factor: 3.575

7.  Doppler assessment of the pulsatility index of the middle cerebral artery during constriction of the fetal ductus arteriosus after indomethacin therapy.

Authors:  G Mari; K J Moise; R L Deter; B Kirshon; J C Huhta; R J Carpenter; D B Cotton
Journal:  Am J Obstet Gynecol       Date:  1989-12       Impact factor: 8.661

8.  A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids.

Authors:  F Hirata; E Schiffmann; K Venkatasubramanian; D Salomon; J Axelrod
Journal:  Proc Natl Acad Sci U S A       Date:  1980-05       Impact factor: 11.205

9.  Indomethacin in the treatment of premature labor. Effects on the fetal ductus arteriosus.

Authors:  K J Moise; J C Huhta; D S Sharif; C N Ou; B Kirshon; N Wasserstrum; L Cano
Journal:  N Engl J Med       Date:  1988-08-11       Impact factor: 91.245

10.  Evaluation of the antiinflammatory and phospholipase-inhibitory activity of calpactin II/lipocortin I.

Authors:  J K Northup; K A Valentine-Braun; L K Johnson; D L Severson; M D Hollenberg
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.